Baseline characteristics
| GUEPARD (N=65) | ESPOIR (N=130) | p Value | |
|---|---|---|---|
| Age mean±SD (years) | 47.9±15.7 | 48.1±11.5 | 0.92 |
| Women, n (%) | 52 (80.0) | 98 (75.4) | 0.59 |
| BMI (kg/m2) | 26.0±4.7 | 26.4±5.5 | 0.59 |
| Symptom duration, months, mean±SD | 5.6±4.6 | 3.5±2.0 | <0.001 |
| IgM rheumatoid factor positive, n (%) | 46 (70.8) | 85 (65.4) | 0.52 |
| Anti-CCP positive, n (%) | 46 (70.8) | 78 (60.0) | 0.16 |
| Pain (VAS 0–100) mean ±SD | 59.5±22.0 | 55.7±20.7 | 0.23 |
| Patient global assessment (VAS 0–100) mean±SD | 68.1±18.7 | 67.9±21.9 | 0.93 |
| Fatigue (VAS 0–100) mean±SD | 57.4±23.6 | 53.4±27.6 | 0.31 |
| Physician global assessment (VAS 0–100) mean±SD | 67.6±17.2 | 65.9±18.1 | 0.53 |
| Tender joint count (mean±SD) | 14.0±6.7 | 14.1±6.8 | 0.93 |
| Swollen joint count (mean±SD) | 10.1±4.9 | 10.7±5.7 | 0.51 |
| ESR (mean±SD) | 37.3±22.4 | 39.5±25.7 | 0.56 |
| CRP (mg/l) mean±SD | 28.7±33.4 | 29.8±32.3 | 0.83 |
| DAS28ESR, mean±SD | 6.24±0.81 | 6.27±0.90 | 0.84 |
| DAS28CRP, mean±SD | 5.82±0.86 | 5.87±0.95 | 0.72 |
| HAQ score, 0–3 scale, mean±SD | 1.37±0.65 | 1.28±0.67 | 0.39 |
| Physical component summaries of SF-36 | 35.4±8.3 | 35.6±7.8 | 0.86 |
| Mental component summaries of SF-36 | 37.7±11.9 | 37.5±11.3 | 0.87 |
| Total SHS, 0–448 scale, mean±SD | 7.7±13.4 | 5.8±8.0 | 0.30 |
| Erosion score, 0–280 scale, mean±SD | 2.4±4.9 | 2.4±3.7 | 0.97 |
| JSN score, 0–168 scale, mean±SD | 5.3±9.5 | 3.5±5.4 | 0.15 |
| Typical erosive disease, n (%) | 13 (20.0) | 22 (16.9) | 0.69 |
BMI, body mass index; CRP, C-reactive protein; DAS28, disease activity score in 28 joints; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; JSN, joint-space narrowing; SHS, modified Sharp/van der Heijde score; SF-36, short form 36 health survey; VAS, visual analogue scale.